Skip to main content
. 2012 Sep 6;7(9):e44707. doi: 10.1371/journal.pone.0044707

Table 1. TCD8+ response to HLA-B18/NY-ESO-188–96.

Group Patients HLA Tetramer or ICS (% of total CD8+ T cells) Vaccination status
HLA-A HLA-B HLA-C Pre-vac Post-vac
NY-ESO-1 ISCOMATRIX™Vaccine 8 A68 B1801, B4402 Cw5, Cw7 0.19 1.220 Boosted
111 A2, A3 B1801, B5101 Cw1,Cw7 2.87 3.76 Pre
102 A3, A11 B1801, B4403 Cw7,Cw16 3.89 4.76 Pre
109 A2 B1801, B4402 Cw5,Cw7 0.140 0.140 Pre
12 A25, A68 B1801, B1402 Cw7,Cw8 ND –*
Placebo controls 115 A2, A30 B1801, B3901 Cw5 ND –*
114 A2, A25 B1801, B3701 Cw6 ND –*
29 A1, A31 B18, B27 Cw2,Cw6 ND –*
113 A3, A25 B18, B7 Cw7, ND –*

Melanoma patients from three clinical trials (see Materials and Methods) with detectable anti-NY-ESO-1 antibody responses and HLA-B18 expression were selected for the screen. T cells from PBMC samples post vaccination (or placebo controls that did not receive the NY-ESO-1 ISCOMATRIX™ vaccine but received diluents) were expanded with 18 mer NY-ESO-179–96 peptide for 12∼15 days and assessed with NY-ESO-188–96 in an ICS assay (only ICS results <0.1% are shown as negative “–” indicated by ‘*’). For patients who showed positive TCD8+ response to this epitope (>0.1%, data not shown) in their post vaccination samples, pre- and post-vaccination PBMC samples were then expanded the same way side-by-side in a second screen intended to determine whether the response was a result of the vaccination. The peptide-specific TCD8+ in the second screen were assessed with the specific HLA-B18/NY-ESO-188–96 tetramer. Tetramer results >0.1% of total CD8+ T cells with a discrete staining pattern are shown; and those results <0.1% are shown as “-”. Pre – pre-existed response; Boosted – vaccine-boosted response; ND – not determined, Pre-vac, prior to vaccination; Post-vac, after vaccination.